Additionally, GSK-3 can control how APP is processed and how tau is phosphorylated by accelerating APP's cellular maturation(Zheng-Fischhöfer et al., 1998), which is thought to take place during the early stages of AD (Gouras et al., 2000), GSK-3 enhances Aβ release. The gene discussed is MAPT; the disease is Alzheimer disease.